Results of multicenter testing of PIK3CA somatic mutations in hormone-receptor positive HER2-negative advanced breast cancer

Aim: Activating somatic mutations in p110α catalytic subunit of PIK3-kinase (PIK3CA) are present in about 40% of breast cancers (BC), and are involved in oncogenesis and cancer growth. PIK3CA inhibitor therapy is approved for patients with advanced HR+/HER2- endocrine-resistant BC with somatic PIK3C...

全面介紹

書目詳細資料

發表在:	Libri Oncologici
Main Authors:	Snježana Ramić, Melita Perić-Balja, Ita Hadžisejić, Zlatko Marušić, Valerija Blažičević, Snježana Tomić
格式:	Article
語言:	英语
出版:	University Hospital for Tumors 2023-01-01
主題:	breast cancer PIK3CA mutation
在線閱讀:	https://hrcak.srce.hr/file/440489